About this trial
As a T2T, our patients with idiopathic inflammatory myopathies will receive pulse therapies with methyprednisolone and/or human intravenous immunoglobulin, or only methyprednisolone at disease onset.
This scheme is an internal routine protocol of our Service.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Idiopathic inflammatory myopathies
Disqualifiers
Inclusion body myositis, muscular dystrophies, neoplasia-associated myopathies, overlapped myopathies, others myopathies
Trial population
Idiopathic inflammatory myopathies
Trial design
Cohort
Prospective
Treatments tested in this trial
Intravenous Infusion
DrugIntravenous infusion of follow medicine at disease onset: methyprednisolone and/or human intravenous immunoglobulin
Treatment groups
Trial outcomes
Primary outcomes
Physician Global Activity
This partially validated tool measures the global evaluation by the treating physician of the overall disease activity of the patient at the time of assessment using a 10 cm. visual analogue scale and a 5 point Likert scale.
Patient/Parent Global Activity -
This partially validated tool measures the global evaluation by the patient, or by the parent if the patient is a minor, of the patient's overall disease activity at the time of assessment using a 10 cm. visual analogue scale.
Manual Muscle Testing
This partially validated tool assesses muscle strength using manual muscle testing (MMT). A 0 - 10 point scale is proposed for use. An abbreviated group of 8 proximal, distal, and axial muscles performs similarly to a total of 24 muscle groups, and is also proposed for use for research studies.
Health Assessment Questionnaire
Define the health assessement questionnaire. Pontuaction: 0.00-3.00
Secondary outcomes
Side effects to treatment (glucocorticoid, immunosuppressants and/or human intravenous immunoglobulin)
Effect of drugs in disease outcomes
Sponsors and contacts
Click on the lead sponsor to view all of their trials.